1. |
Limited evidence to support use of corticosteroids in sarcoidosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Azithromycin: cost advantage over standard penicillins for treating CAP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 5-6
Pamela Hunter,
Preview
|
|
摘要:
Community-acquired pneumonia (CAP) is a common and widespread disease in both developed and developing countries. The disease has a high economic cost in terms of the direct costs associated with treatment and follow-up treatment if primary therapy fails, as well as the indirect costs associated with time off work. Empirical therapy is generally indicated for the treatment of CAP as treatment must often commence before the causative organisms are known. Some of the common organisms that cause CAP are either intrinsically resistant to, or have developed resistance to, frequently used β-lactams. The azalide antibacterial azithromycin is related to macrolides and has a broad spectrum of antibacterial activity which includes all common aetiological agents of CAP. In addition, it is well absorbed from the gastrointestinal tract, is well tolerated, and only requires administration once daily. Azithromycin is, however, more expensive than traditional penicillins, such as benzylpenicillin, a low-cost agent that is still used in countries with limited healthcare budgets. A pharmacoeconomic study presented at the 6th International Conference on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICMAS-KO) [Bologna, Italy; January 2002], showed that azithromycin was more cost effective than benzylpenicillin in the empirical treatment of CAP in servicemen in the Ukraine.1
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Antibacterial recommendations not being followed in UTIs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Benefits of tiotropium bromide maintained during long-term use |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Superior myocardial salvage with stenting following AMI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Etanercept provides relief in psoriasis and psoriatic arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1330,
2002,
Page 11-13
Raewyn Poole,
Preview
|
|
摘要:
Etanercept ['Enbrel'] is effective and well tolerated in patients with psoriasis and/or psoriatic arthritis, according to the results of two placebo-controlled studies presented at the 60th Annual Meeting of the American Academy of Dermatology [New Orleans, US; February 2002].*A phase III study involving patients with psoriatic arthritis demonstrated that treatment with etanercept significantly improved symptoms of both psoriasis and psoriatic arthritis, in addition to significantly reducing disability and improving quality of life. In 24-week results from a phase II study, 56% of patients randomised to etanercept monotherapy achieved improvements of ≥ 75% in Psoriasis Area and Severity Index (PASI) scores.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|